Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products. The company integrates artificial intelligence, genomics, and living biological systems to decode disease mechanisms and identify therapeutic targets. Its pipeline includes genetically modified dendritic cell therapeutic vaccines, such as RENB-DC11 for pancreatic cancer and RENB-DC20 for breast cancer treatment. Lunai Bioworks operates through multiple segments, including RENB, BioSymetrics, and RENC. The company employs proprietary AI platforms combined with zebrafish models to uncover drug efficacy, safety profiles, and clinical biomarkers that traditional research methods may overlook. By integrating phenotypic, proteomic, and genomic data, Lunai Bioworks aims to create clear pathways from disease discovery to patient benefit, focusing on precision medicine approaches for oncology and other therapeutic areas. Headquartered in Los Angeles, California, the company serves both the United States and Netherlands markets.
Website2080 Century Park East
Los Angeles, CA, 90067
United States
Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics subsidiary, supporting the development of structure-based screening tools for chemical outputs generated by large language models and other artificial intelligence systems. The study evaluates predicting acetylcholinesterase ("AChE") inhibition directly from molecular structure as a model-agnostic component of the Company's broader chemical-safety and bios
Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC).
Investors talking about RENB also mention
What share of all stock conversation is about RENB?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about RENB that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 50.65% -39.58 | ||
| Bearish | — | — | — | 49.35% +39.58 |
Of the messages about RENB that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Analysts | — | — | — | 37.99% | ||
| Announcements | — | — | — | 26.47% | ||
| Controversies | — | — | — | 1.23% | ||
| Earnings | — | — | — | 0% | ||
| Macro | — | — | — | 33.09% | ||
| Technical Analysis | — | — | — | 1.23% |
Of the messages about RENB, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | — | 1.4% | ||
| Newcomers | — | — | — | 98.6% |